STRO - SUTRO BIOPHARMA, INC.

21.31
1.610   7.555%

Share volume: 198,657
Last Updated: 03-04-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.44%

PREVIOUS CLOSE
CHG
CHG%
$19.70
1.61
0.08%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
10%
Profitability 0%
Dept financing 12%
Liquidity 37%
Performance 13%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
3.72%
1 Month
45.96%
3 Months
146.07%
6 Months
1,910.38%
1 Year
1,466.91%
2 Year
369.38%
Key data
Stock price
$21.31
P/E Ratio 
0.00
DAY RANGE
$19.74 - $21.42
EPS 
-$2.55
52 WEEK RANGE
$0.52 - $21.42
52 WEEK CHANGE
$1,349.66
MARKET CAP 
73.618 M
YIELD 
N/A
SHARES OUTSTANDING 
85.135 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-12-2025
BETA 
3.65
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$94,764
AVERAGE 30 VOLUME 
$131,221
Company detail
CEO: William J. Newell
Region: US
Website: sutrobio.com
Employees: 240
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Sutro Biopharma, Inc. focuses on creating protein therapeutics for cancer and autoimmune disorders. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma.

Recent news